Releases

Date Title and Summary Additional Formats
Toggle Summary Veloxis Pharmaceuticals Releases Annual Report for 2016
Company Release no. 03/2017    To: NASDAQ Copenhagen A/S                             Copenhagen, Denmark, 28 February 2017   Veloxis Pharmaceuticals Releases Annual Report for 2016   Veloxis Pharmaceuticals A/S (OMX: VELO) today published its Annual Report for the financial year 2016.  This company
View HTML
Toggle Summary Veloxis Pharmaceuticals Announces New Jersey Office Closure
Investor News no. 02/2017   To: NASDAQ Copenhagen A/S                            Copenhagen, Denmark, 28 February 2017       Veloxis Pharmaceuticals Announces New Jersey Office Closure   Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that its US subsidiary, Veloxis Pharmaceuticals Inc.,
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Annual Report 2016—Results from 1 January to 31 December, 2016
Investor News no. 01/2017     To: NASDAQ Copenhagen A/S                                       Copenhagen, Denmark, 23 February 2017     Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Annual Report 2016— Results from  1 January to 31 December, 2016   Veloxis Pharmaceuticals A/S (OMX:
View HTML
Toggle Summary Veloxis Pharmaceuticals Announces Amended and Restated Loan and Security Agreement
Company Release no. 02/2017   To: NASDAQ Copenhagen A/S                                    Copenhagen, Denmark, 08 February 2017   Veloxis Pharmaceuticals Announces Amended and Restated Loan and Security Agreement   Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that it has agreed to amend
View HTML
Toggle Summary Veloxis Pharmaceuticals Announces Updated Financial Calendar for 2017
Company Release no. 01/2017   To: NASDAQ Copenhagen A/S                                    Copenhagen, Denmark, 25 January 2017   Veloxis Pharmaceuticals Announces Updated Financial Calendar for 2017     Veloxis Pharmaceuticals A/S (OMX: VELO) today updated its financial calendar for 2017.  The
View HTML
Toggle Summary Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 31 December 2016
Company Announcement no. 27/2016       To: NASDAQ Copenhagen A/S                    Copenhagen, Denmark, 31 December 2016   Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 31 December 2016   Veloxis Pharmaceuticals A/S announces, in accordance with Section 10 of
View HTML
Toggle Summary Veloxis Pharmaceuticals Announces Financial Calendar for 2017
Company Announcement no. 26/2016   To: NASDAQ Copenhagen A/S                                    Copenhagen, Denmark, 20 December 2016   Veloxis Pharmaceuticals Announces Financial Calendar for 2017   Veloxis Pharmaceuticals A/S (OMX: VELO) today announced its financial calendar for 2017.
View HTML
Toggle Summary Veloxis Increases Share Capital in Connection with Exercise of Warrants
Company Announcement no. 25/2016   To: NASDAQ OMX Copenhagen A/S                            Copenhagen, 19 December 2016   Veloxis Increases Share Capital in Connection with Exercise of Warrants   Veloxis Pharmaceuticals A/S announces that the company's capital has been increased by 1,500,000 new
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S Establishes New Warrant Programme
Company Announcement no. 24/2016   To: NASDAQ Copenhagen A/S                     Copenhagen, Denmark, 17 November 2016   Veloxis Pharmaceuticals A/S establishes new Warrant Programme Today, the Board of Directors of Veloxis has decided to establish a new warrant programme for board members and
View HTML
Toggle Summary Veloxis Pharmaceuticals Announces Financial Results for the First Nine Months of 2016 and Provides Corporate Update
Highlights   ·        Envarsus XR reaches an estimated 1,200 patients on therapy in the U.S. and an estimated 2,000 patients in EU countries ·        Total net revenues for Veloxis grew 27% in the third quarter of 2016 over the second quarter of 2016 as launch activities for Envarsus XR in the U.S.
View HTML
Toggle Summary Veloxis Announces the Total Number of Shares and Voting Rights
Company Announcement no. 22/2016     To: NASDAQ OMX Copenhagen A/S                        Copenhagen, Denmark, 30 September 2016     Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 30 September 2016 Veloxis Pharmaceuticals A/S announces in accordance with Section
View HTML
Toggle Summary Veloxis Increases Share Capital in Connection with Exercise of Warrants
Company Announcement no. 21/2016     To: NASDAQ OMX Copenhagen A/S                        Copenhagen, Denmark, 20 September 2016     Veloxis Increases Share Capital in Connection with Exercise of Warrants   Veloxis Pharmaceuticals A/S announces that the company's capital has been increased by
View HTML
Toggle Summary Veloxis Increases Share Capital in Connection with Exercise of Warrants
Company Announcement no. 20/2016   To: NASDAQ OMX Copenhagen A/S                         Copenhagen, Denmark, 6 September 2016       Veloxis Increases Share Capital in Connection with Exercise of Warrants   Veloxis Pharmaceuticals A/S announces that the company's capital has been increased by
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S Completes Closure of its Hørsholm, Denmark Office
Investor Service Announcement no. 5/2016   To: NASDAQ Copenhagen A/S                                              Copenhagen, Denmark, 31 August 2016     Veloxis Pharmaceuticals A/S Completes Closure of its Hørsholm, Denmark Office   Veloxis Pharmaceuticals A/S has completed the closure of its
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S Establishes New Warrant Programme
Company Announcement no. 19/2016   To: NASDAQ Copenhagen A/S                                              Copenhagen, Denmark, 25 August 2016       Veloxis Pharmaceuticals A/S Establishes New Warrant Programme   Today, the Board of Directors of Veloxis has decided to establish a new warrant
View HTML
Toggle Summary Veloxis Pharmaceuticals Announces Financial Results for the First Six Months of 2016 and Provides Corporate Update
  Highlights   FDA approves label enhancement for Envarsus XR® which establishes dosing and PK profile in African-Americans and rapid metabolizers of tacrolimus Favorable signal in cardiovascular outcomes in African-Americans from ASERTAA trial, and two-year safety results from STRATO trial
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S - Passing of Extraordinary General Meeting
Company Announcement no. 17/2016     To: NASDAQ Copenhagen A/S                  Copenhagen, Denmark, July 26, 2016     Veloxis Pharmaceuticals A/S - Passing of Extraordinary General Meeting   Summary: At Veloxis Pharmaceuticals A/S' Extraordinary General Meeting held earlier today, the proposal
View HTML
Toggle Summary Notice to Convene Extraordinary General Meeting
Company Announcement no. 16 /2016     To: NASDAQ OMX Copenhagen A/S                                        Hørsholm, Denmark, 1 July 2016     Notice to Convene Extraordinary General Meeting   The board of directors of Veloxis Pharmaceuticals A/S, CVR no.
View HTML
Toggle Summary Veloxis announces the total number of shares and voting rights in the company as of 30 June 2016
Company Announcement no. 15/2016    To: NASDAQ OMX Copenhagen A/S                                           Hørsholm, Denmark, 30 June 2016      Veloxis announces the total number of shares and voting rights in the company as of 30 June 2016   Veloxis Pharmaceuticals A/S announces in accordance
View HTML
Toggle Summary Veloxis Receives Envarsus XR® Package Insert Label Enhancements Based on Study of African-American Transplant Recipients
Company Announcement no. 14/2016     To: NASDAQ OMX Copenhagen A/S                                                 Hørsholm, Denmark, 29 June 2016     Veloxis Receives Envarsus XR® Package Insert Label Enhancements Based on Study of African-American Transplant Recipients   Veloxis Pharmaceuticals
View HTML
Toggle Summary Veloxis increases share capital in connection with exercise of warrants
Company Announcement no. 13/2016    To: NASDAQ OMX Copenhagen A/S                                          Hørsholm, Denmark, 13 June 2016      Veloxis increases share capital in connection with exercise of warrants   Veloxis Pharmaceuticals A/S announces that the company's capital has been
View HTML
Toggle Summary Veloxis to Present Company Overview and Envarus® XR (tacrolimus extended-release tablets) Launch Update at Jefferies 2016 Healthcare Conference
Investor service announcement no. 4/2016       To: NASDAQ OMX Copenhagen A/S                            Hørsholm, Denmark, 8 June 2016       Veloxis to Present Company Overview and Envarus ® XR (tacrolimus extended-release tablets) Launch Update at Jefferies 2016 Healthcare Conference   Veloxis
View HTML
Toggle Summary Veloxis announces the total number of shares and voting rights in the company as of 31 May 2016
Company Announcement no. 12/2016    To: NASDAQ OMX Copenhagen A/S                                           Hørsholm, Denmark, 31 May 2016      Veloxis announces the total number of shares and voting rights in the company as of 31 May 2016   Veloxis Pharmaceuticals A/S announces in accordance with
View HTML
Toggle Summary Veloxis increases share capital in connection with exercise of warrants
Company Announcement no. 11/2016   To: NASDAQ OMX Copenhagen A/S                                          Hørsholm, Denmark, 30 May 2016      Veloxis increases share capital in connection with exercise of warrants   Veloxis Pharmaceuticals A/S announces that the company's capital has been increased
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S establishes new Warrant Programme
Company Announcement no. 10/2016   To: NASDAQ Copenhagen A/S                                                                                                                        Hørsholm, Denmark, 19 May, 2016   Veloxis Pharmaceuticals A/S establishes new Warrant Programme   Today, the Board of
View HTML
Toggle Summary Veloxis Pharmaceuticals announces financial results for the first three months of 2016
Veloxis Pharmaceuticals announces financial results for the first three months of 2016 Company Announcement no. 9/2016   To: NASDAQ OMX Copenhagen A/S                                                 Hørsholm, Denmark, 18 May, 2016     Veloxis Pharmaceuticals announces financial results for the
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Interim Report for the first Quarter 2016 — results from 1 January to 31 March, 2016
Investor service announcement no. 3/2016    To: NASDAQ OMX Copenhagen                                                    Hørsholm, Denmark, 11 May, 2016      Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Interim Report for the first Quarter 2016 — results from 1 January to 31
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S establishes new Warrant Programme
Company Announcement no. 8/2016     To: NASDAQ Copenhagen A/S                                                              Hørsholm, Denmark, April 7, 2016     Veloxis Pharmaceuticals A/S establishes new Warrant Programme   Today, the Board of Directors of Veloxis has decided to establish a new
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S - Passing of Annual General Meeting
Company Announcement no. 7/2016     To: NASDAQ Copenhagen A/S                                                             Hørsholm, Denmark, April 6, 2016     Veloxis Pharmaceuticals A/S - Passing of Annual General Meeting   Summary: At Veloxis Pharmaceuticals A/S' Annual General Meeting held
View HTML
Toggle Summary Veloxis announces change in management
Company Announcement no. 6/2016     To: NASDAQ Copenhagen A/S                                             Hørsholm, Denmark, 6 April, 2016     Veloxis announces change in management     Veloxis Pharmaceuticals A/S (NASDAQ: VELO) announced today that Johnny Stilou will step down as EVP & Chief
View HTML
Toggle Summary Veloxis offentliggør ændring af ledelsen
Selskabsmeddelelse nr. 6/2016     Til: NASDAQ Copenhagen A/S                                                              Hørsholm, 6 april 2016     Veloxis offentliggør ændring af ledelsen     Veloxis Pharmaceuticals A/S (NASDAQ: VELO) har i dag offentliggjort, at Johnny Stilou fratræder som EVP &
View HTML
Toggle Summary Veloxis annoncerer det samlede antal aktier og stemmerettigheder i selskabet pr. 31. marts 2016
Selskabsmeddelelse nr. 5/2016     Til: NASDAQ OMX Copenhagen A/S                                                    Hørsholm, den 31. marts 2016     Veloxis annoncerer det samlede antal aktier og stemmerettigheder i selskabet pr. 31. marts 2016   Veloxis Pharmaceuticals A/S meddeler hermed i
View HTML
Toggle Summary Veloxis announces the total number of shares and voting rights in the company as of 31 March 2016
Company Announcement no. 5/2016   To: NASDAQ OMX Copenhagen A/S                                           Hørsholm, Denmark, 31 March 2016      Veloxis announces the total number of shares and voting rights in the company as of 31 March 2016   Veloxis Pharmaceuticals A/S announces in accordance
View HTML
Toggle Summary Veloxis udsteder nye aktier i forbindelse med udnyttelse af warrants
Selskabsmeddelelse nr. 4/2016     Til: NASDAQ OMX Copenhagen A/S                                                   Hørsholm, den 30. marts 2016     Veloxis udsteder nye aktier i forbindelse med udnyttelse af warrants   Veloxis Pharmaceuticals A/S meddeler hermed, at selskabet har forhøjet sin
View HTML
Toggle Summary Veloxis increases share capital in connection with exercise of warrants
Company Announcement no. 4/2016   To: NASDAQ OMX Copenhagen A/S                                          Hørsholm, Denmark, 30 March 2016      Veloxis increases share capital in connection with exercise of warrants   Veloxis Pharmaceuticals A/S announces that the company's capital has been
View HTML
Toggle Summary Indkaldelse til ordinær generalforsamling
Selskabsmeddelelse nr. 3/2016     Til: NASDAQ OMX Copenhagen A/S                                                              Hørsholm, 15. marts 2016   Indkaldelse til ordinær generalforsamling Bestyrelsen for Veloxis Pharmaceuticals A/S, CVR-nr. 26 52 77 67 ("Selskabet"), indkalder hermed til
View HTML
Toggle Summary Notice to Convene Annual General Meeting
Company Announcement no. 3/2016     To: NASDAQ OMX Copenhagen A/S                                                       Hørsholm, Denmark, 15 March, 2016     Notice to Convene Annual General Meeting   The board of directors of Veloxis Pharmaceuticals A/S, CVR no.
View HTML
Toggle Summary Veloxis Pharmaceuticals publishes Annual Report 2015
Company Announcement no. 2/2016   To: NASDAQ OMX Copenhagen A/S                                                         Hørsholm, Denmark, 9 March 2016      Veloxis Pharmaceuticals p ublishes Annual Report 2015   Veloxis Pharmaceuticals A/S (OMX: VELO) (‘Veloxis') today published the annual report
View HTML
Toggle Summary Veloxis Pharmaceuticals offentliggør årsrapport 2015
Selskabsmeddelelse nr. 2/2016   Til: NASDAQ OMX Copenhagen A/S                                                                           Hørsholm, 9. marts 2016     Veloxis Pharmaceuticals offentliggør årsrapport 2015   Veloxis Pharmaceuticals A/S (OMX:VELO) (‘Veloxis') har i dag offentliggjort
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S moves Danish activates to the U.S.
Investor service announcement no. 2/2016                                                                                                        Hørsholm, Denmark, 9 March, 2016    Veloxis Pharmaceuticals A/S moves Danish activates to the U.S.   Veloxis Pharmaceuticals A/S ("Veloxis") has decided to
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S er vært for en telekonference i forbindelse med offentliggørelsen af årsrapporten 2015 — resultater fra 1. januar til 31. december 2015
Investor service meddelelse nr. 1/2016    Til: NASDAQ OMX København                                                               Hørsholm, den 2 marts 2016    Veloxis Pharmaceuticals A/S er vært for en telekonference i forbindelse med offentliggørelsen af årsrapporten 2015 — resultater fra 1.
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Annual report 2015 — results from 1 January to 31 December, 2015
Investor service announcement no. 1/2016    To: NASDAQ OMX Copenhagen                                                   Hørsholm, Denmark, 2 March, 2016    Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Annual report 2015 — results from 1 January to 31 December, 2015   Veloxis
View HTML
Toggle Summary Veloxis appoints Alastair McEwan as new Chief Operating Officer
Company Announcement no. 1/2016     To: NASDAQ Copenhagen A/S                                             Hørsholm, Denmark, 29 February, 2016     Veloxis appoints Alastair McEwan as new Chief Operating Officer     Veloxis Pharmaceuticals A/S (NASDAQ: VELO) announced today that Alastair McEwan has
View HTML
Toggle Summary Veloxis udnævner Alastair McEwan til ny Chief Operating Officer
Selskabsmeddelelse nr. 1/2016     Til: NASDAQ Copenhagen A/S                                             Hørsholm, 29. februar 2016     Veloxis udnævner Alastair McEwan til ny Chief Operating Officer     Veloxis Pharmaceuticals A/S (NASDAQ: VELO) har i dag meddelt, at Alastair McEwan er udnævnt til
View HTML
Toggle Summary Veloxis offentliggør ændring af ledelsen
Selskabsmeddelelse nr. 27/2015     Til: NASDAQ Copenhagen A/S                                                                   Hørsholm, 10. december 2015     Veloxis offentliggør ændring af ledelsen     Veloxis Pharmaceuticals A/S (NASDAQ: VELO) har i dag offentliggjort, at Dr. William J.
View HTML
Toggle Summary Veloxis announces change in management
Company Announcement no. 27/2015     To: NASDAQ Copenhagen A/S                                             Hørsholm, Denmark, 10 December, 2015     Veloxis announces change in management     Veloxis Pharmaceuticals A/S (NASDAQ: VELO) announced today that Dr. William J.
View HTML
Toggle Summary Veloxis Launches Envarsus® XR for Treatment of Kidney Transplant Patients in U.S.
Company Announcement no. 26/2015    To: NASDAQ OMX Copenhagen A/S                                    Hørsholm, Denmark, 7 December, 2015    Veloxis Launches Envarsus ® XR for Treatment of Kidney Transplant Patients in U.S. Envarsus ® XR is Indicated for Patients Converted from Tacrolimus
View HTML
Toggle Summary Veloxis markedsfører Envarsus® XR til behandling af nyretransplantationspatienter i U.S.A.
Selskabsmeddelelse nr. 26/2015    Til: NASDAQ OMX Copenhagen A/S                                                        Hørsholm, 7. december 2015    Veloxis markedsfører Envarsus ® XR til behandling af nyretransplantationspatienter i U.S.A. Envarsus ® XR er indikeret til patienter, som er
View HTML
Toggle Summary Veloxis increases share capital in connection with exercise of warrants
Company Announcement no. 25/2015    To: NASDAQ OMX Copenhagen A/S                            Hørsholm, Denmark, 3 December 2015      Veloxis increases share capital in connection with exercise of warrants   Veloxis Pharmaceuticals A/S announces that the company's capital has been increased by
View HTML
Toggle Summary Veloxis udsteder nye aktier i forbindelse med udnyttelse af warrants
Selskabsmeddelelse nr. 25/2015    Til: NASDAQ OMX Copenhagen A/S                                     Hørsholm, den 3. december 2015    Veloxis udsteder nye aktier i forbindelse med udnyttelse af warrants   Veloxis Pharmaceuticals A/S meddeler hermed, at selskabet har forhøjet sin aktiekapital med
View HTML